Abstract
The chimeric CYP21P/CYP21 gene is a consequence of a 26- or 32-kb deletion in the C4-CYP21 repeat module of CYP21P, tenascin A (XA), serine/threonine nuclear protein kinase (RP2), and the C4B and CYP21 genes in congenital adrenal hyperplasia (CAH) with steroid 21-hydroxylase deficiency. To date, there have been three distinct chimeras found in CAH patients in ethnic Chinese. Initiation for production of these molecules is proposed to be chi-like sequences and a minisatellite consensus existing in several noncoding regions in CYP21 genes. These molecules have the 5’ end of the CYP21P-specific sequence in common but differ in the 3’ end of CYP21-specific genes. In addition, there appears to be a 3.2-kb fragment generated by Taq I digestion, which leads to allele dropout in PCR amplification for detecting the aberrant splicing site of the IVS2 −12A/C>G mutation at nucleotide (nt) 655 in the CYP21 gene. Therefore, the chimeric CYP21P/CYP21 cannot be detected by conventional methods. It has been demonstrated that a PCR product amplified with allele-specific primers covering tenascin B (TNXB) to the 5’ end of the CYP21 gene combined with Southern analysis by Ase I and Nde I digestion may be used for identifying the chimera in the CYP21 gene.
Similar content being viewed by others
Introduction
Congenital adrenal hyperplasia (CAH) is a common autosomal-recessive disorder caused mainly by defects in the steroid 21-hydroxylase (CYP21) gene. More than 90% of CAH cases are caused by mutation of the CYP21 gene (White and Speiser 2000). To date, 72 different CYP21 mutations have been reported (Human Gene Mutation Database 2003), among which 57 are spontaneous mutations. The remaining 15 mutations (Lee 2001) are believed to be products of intergenic recombinations of DNA sequences between the CYP21 gene and the highly homologous CYP21P pseudogene. These mutations can be identified by allele-specific oligonucleotide (ASO) (Speiser et al. 1994) and reverse dot-blot hybridizations (Yang et al. 2001), direct DNA sequencing (Tajima et al. 1993), PCR/ligase (Day et al. 1995), and the amplification-created restriction site (ACRS) method (Lee et al. 1996). For some unknown defective loci somewhere within the CYP21 gene, SSCP (Tajima et al. 1993; Lee et al. 1998) and denatured gradient gel electrophoresis (DGGE) (Ohlsson et al. 1999) may be applied to possibly find novel mutations in the CYP21 gene. However, all these applications for mutational detection should be carried out using the functional CYP21 gene. Therefore, the primary PCR product of the CYP21 gene has to be prepared by differential PCR amplification to eliminate any CYP21P contamination prior to mutational analysis. Most primary PCR products are derived by multiple allele-specific primer sets to generate the CYP21 gene in two PCR fragments using two-to-three-step PCR amplification (Day et al. 1996; Ordonez-Sanchez et al. 1998). For convenience and for amplification efficiency, a single, complete CYP21-specific amplification performed in a single reaction mixture is used (Lee et al. 1996). This PCR product contains the entire CYP21 gene, which can be cloned and characterized by an expression analysis (Lee and Chang 2001).
Identification of the 30-kb gross gene deletion (White et al. 1984) encompassing the C4A and CYP21 genes in the C4-CYP21 repeat module was controversial in the past (Miller 1988; White et al. 1988; Morel et al. 1989), even though the deletion had been demonstrated by pulse field electrophoresis (Collier et al. 1989). The ambiguity was mainly caused by the lack of detailed information on the extent of gene conversion or deletion in the C4-CYP21 repeat module or RCCX module (Shen et al. 1994) in chromosome 6p21.3. This module includes CYP21P, XA (Gitelman et al. 1992), the serine/threonine nuclear protein kinase RP (Yang et al. 1998), C4, CYP21, and tenascin B (TNXB) (Bristow et al. 1993) genes (Fig. 1A). The C4 protein is coded by two genes, C4A and C4B. Long gene (20.4 kb) or short gene (14.1 kb) of the C4 is due to the presence of an endogenous retrovirus sequence (6.7 kb), HERV-K (C4), in intron 9 (Yu 1991). TNXB, in the downstream CYP21 gene, is partially duplicated in the downstream CYP21P gene, where it is termed XA gene (TNXA). Both XA and TNXB are transcribed on the opposite strand. The RP gene contains two duplicated genes, RP1 and RP2. The RP2 gene is truncated and corresponding to RP1 adjacent to TNXA (Yang et al. 1999). These tandemly arranged genes, CYP21P-XA-RP2-C4B-CYP21-TNXB, are designated as the RCCX module. At present, such a deletion is considered to result from an unequal crossover in meiosis occurring in 20% of alleles in most populations (White and Speiser 2000). However, the population frequency is dependent on the population studied (White and Speiser 2000). Three reports (Levo and Partanen 1997; Koppens et al. 2000;L’Allemand et al. 2000) pointed out that such a gross 30-kb deletion consisted of a fused CYP21 gene, with its 5’ and 3’ ends corresponding to CYP21P and CYP21 respectively, and the product appearing as a 3.2-kb Taq I fragment in Southern blot analysis. In a recent study (Lee et al. 2003a), it demonstrated that such a 30-kb gene deletion in fact is a chimeric CYP21P/CYP21 formation caused by multiple gene deletions, including XA, RP2, and C4B, and between unequal parts of the CYP21P and CYP21 genes in the C4-CYP21 repeat module (Fig. 1A). Such a gene deletion or gene conversion is traditionally detected by Southern blotting with multiple isotope-labeled probes and RFLP analysis; Taq I generates the 3.7-kb (functional) and 3.2-kb (pseudogene) fragments, while Bgl II produces the 11-kb (functional) and 12-kb (pseudogene) fragments. These two approaches to fragment analysis have been used since 1984 (White et al. 1984; Donohoue et al. 1989; Koppens et al. 2000; L’Allemand et al. 2000). However, the method is laborious and indirect, and densitometric screening of fragments is error prone, although a nonisotopic Southern procedure was later described (Krone et al. 1998).
Causes of the formation of the chimeric CYP21P/CYP21 gene
Basically, the chimera features fused genes. In the case of P450c21, chimeric CYP21P/CYP21 is formed by recombination of the duplicated CYP21P and CYP21 genes, but the cause of formation is unclear. However, several possibilities have been proposed:
Proximity to the human major histocompatibility complex (MHC)
In order to increase diversity of transplantation antigens and to maximize versatility of immune responses in humans, there is a high recombination rate in the MHC of the HLA complex. Both the CYP21P and CYP21 genes are on chromosome 6p21.3, adjacent to and alternating with the C4A and C4B genes encoding the fourth components of the serum complement (White et al. 1984), located within the HLA complex. As a result, the frequency of recombination events between these two genes is relatively high in human populations.
Homologous recombination
Because the exon sequence of the CYP21P pseudogene shares 98% nucleotide sequence homology with functional CYP21 (Higashi et al. 1986; White et al. 1986), homologous recombination of misalignment may occur at meiosis (Tusie-Luna and White 1995). It has been noted that the region between intron 2 and the 3’ end of exon 3 in CYP21 is considered a hotspot for recombinations and microconversions (Tusie-Luna and White 1995).
Initiation by the existence of a chi-like sequence and tandem-repetitive minisatellite consensus
Sequences such as chi (GCTGGTGG; Smith et al. 1981) and the tandem-repetitive minisatellite consensus (GGGCAGGAXG; Jeffreys et al. 1985) are important for genetic recombination in eukaryotic cells. These sequences may be recognition sites for the recombinase complex responsible for gene recombination. It has been pointed out that the chi-like sequence GCTGGGG is present several times in the CYP21P and CYP21 gene (Table 1). Most of them appear in intron sequence. Two distinct areas of nucleotides (nt), 470–999 and 1375–1993 (Higashi et al. 1986), of CYP21 genes have been proposed to be related to crossover regions (Donohoue et al. 1989). On the other hand, there are three minisatellite consensus sequences located in the CYP21 gene at nt 1113–1121 (IVS4), 1950–1959 (IVS7), and the 3’ untranslated region from nt 2710–2719 (Urabe et al. 1990) (Table 1). One report suggested unequal crossover in exon 7 sequences (Chu et al. 1992).
Types of chimeric CYP21P/CYP21
There have been various studies (White et al. 1988; Sinnott et al. 1990; Levo and Partanen 1997; Koppens et al. 2000) indicating hybrid genes with the 30-kb deletion between CYP21P and CYP21 genes in Caucasians. Several studies (Lee et al. 2002; Lee et al. 2003a) have shown that there are three distinct chimeric CYP21P/CYP21s in the CYP21 gene in the ethnic Chinese population in Taiwan. These three molecules are designated CH-1, CH-2, and CH-3 (Fig. 1B) (Table 2). Results indicated that CH-1 has an identical sequence to the CYP21P gene from exons 1–3 without the mutation at I172 N (nt 999) (Fig. 1B) (Table 2), CH-2 is identical to the CYP21P gene from exons 1–5 of D183E (nt 1117), and CH-3 is identical in sequence to the CYP21P gene from exons 1–8 of Q318X (nt 1994) without the R356 W mutation (Fig. 1B) (Table 2) (Lee et al. 2002; Lee et al. 2003a). In addition to these, the three chimeric CYP21P/CYP21s possess identical 5’ ends of the CYP21P gene (Table 2) (Lee et al. 2002; Lee et al. 2003a). Obviously, structural differences of the three chimeras show that these molecules are composed of unequal sequences between the CYP21P and CYP21 genes leading to the production of a variety of structural arrangements.
Properties of the chimeric CYP21P/CYP21 gene
Allele dropout in PCR amplification for detecting the IVS2 −12A/C>G mutation
As previously reported (Day et al. 1996), the allele dropout that occurs in the detection of the IVS2 −12A/C>G mutation at nt 655 (Higashi et al 1986) is due to preferential amplification of DNA segments and is an artifact caused by polymerase (Schulze et al. 1998). This leads to an excessively high frequency of apparent homozygosity and genotyping discordance between parents and probands. A previous study (Lee et al. 2000) pointed out that allele dropout was associated with unequal amplification in the presence of the chimeric CYP21P/CYP21, which lacks a specific primer for amplification during analysis of the mutation IVS2 −12A/C>G. In addition, a recent study (Lee et al. 2003b) found that a haplotype of the CYP21 gene with the mutations of IVS2 −12A/C>G and 707–714delGAGACTAC (Higashi et al. 1986) is a case of gene deletion including the CYP21P, XA, RP2, and C4B genes in the C4-CYP21 repeat module. This finding further confirms that allele PCR dropout in previous PCR analyses was in fact caused by the presence of the 5’ end region of the CYP21P sequence, which is consistent with our previous suggestion (Lee et al. 2000). Since an antisense primer anchored at nt 707–714 of CYP21 has been used in most primary PCR amplifications (Tajima et al. 1993; Day et al. 1996; Koppens et al. 2000) to eliminate CYP21P contamination, it may have led to PCR dropout in detecting CYP21 mutations of IVS2–12A/C>G combined with707–714delGAGACTAC and the chimeric CYP21P/CYP21.
Production of a 3.2-kb fragment by Taq I digestion
Since three chimeric CYP21P/CYP21 genes contain an identical sequence in the 5’ end of CYP21P (Table 2) resulting in a frameshift of the sequence upstream of CYP21P, each of the chimeras has the base T at nt −209 replaced by C (Higashi et al. 1986) (Table 2), producing a Taq I restriction site in these defective CYP21 alleles and subsequently leading to a 3.2-kb Taq I fragment (Fig. 2A). Therefore, the assumption that the 3.2-kb fragment from conventional Southern analysis is a deletion product of the CYP21 gene is incorrect.
Production of a 9.3-kb fragment resulting from deletion of the TNXA, RP2, and C4B genes
In the traditional Southern blot analysis, Taq I generates a 3.7-kb (functional) and a 3.2-kb (pseudogene) fragment, and Bgl II produces an 11-kb (functional) and a 12-kb (pseudogene) fragment, which cannot indicate detailed information on the extent of gene conversion or deletion in the RCCX module. Therefore, a study (Lee et al. 2003a) using two restriction endonucleases, Ase I and Nde I, with a single probe was used to identify the interchange region. Results revealed that deletion of the TNXA, RP2, and C4B genes (Fig. 1A) leads to formation of the chimeric CYP21P/CYP21 in a 9.3-kb fragment (Fig. 2B, lane M). This improves the detection protocol for gene deletions and conversions in the RCCX module (Fig. 1A). Given the potential for variations and a lack of information about the C4B gene (Yu 1991) in Chinese populations, the size of the RCCX modular deletion may either be 26 or 32 kb long (Fig. 1A) (Lee et al. 2003a).
Biological activity of the chimeric CYP21P/CYP21
Because the 5’ end of the three different chimeric CYP21P/CYP21 genes have identical sequences with that of CYP21P (Table 2), nucleotide substitutions at these sites from CYP21P- to CYP21-specific sequences at nt −103, −110, and −123 (Higashi et al. 1986) cause a five-fold decrease in transcriptional activity and in the ability of the promoter to bind with the Sp1 protein (Chang and Chung 1995). At nt 655 (Higashi et al. 1986) of the IVS2 -12A/C>G mutation, the aberrant splicing site results in very low but measurable enzyme levels (Higashi et al. 1988a). In addition, deletion of 707–714delGAGACTAC leads to a frameshift mutation, which forms a TGA stop codon downstream at nt 830 (Higashi et al. 1986) and produces a truncated protein in translation. Taken together, these three kinds of chimeric CYP21P/CYP21 have no steroid 21-hydroxylase activity. However, the hybrid gene reported by the study (L’Allemand et al. 2000) without these two mutations had low 21-hydroxylase activity with a defect in P30L.
Identification of the chimeric CYP21P/CYP21 gene
Identification of gene deletions and conversions is still being studied by Southern blot analysis with oligonucleotides (Higashi et al 1988b; Donohoue et al. 1989; Helmberg et al. 1992; Tusie-Luna and White 1995) or DNA probes (Krone et al. 1998; Koppens et al. 2000; L’Allemand et al. 2000) for hybridization. There are two established strategies of PCR amplification for identifying the CYP21 gene:
-
1.
Mixed-primer amplification of the 3.5-kb PCR product: To collect the chimeric CYP21P/CYP21, three primers (Table 3) containing a 3’-specific primer for the CYP21 gene and two different 5’-primers for both CYP21 and CYP21P used to amplify the normal CYP21, and the chimera have been successfully used for CAH diagnosis (Lee et al. 2000; 2002). The 3.5-kb fragments (Lee et al. 2000; 2002) covering sequences of the CYP21 gene from −313 to 3170 (Higashi et al. 1986) were generated. The PCR products were analyzed using the ACRS primer for mutational analysis (Fig. 1B) (Lee et al. 1996).
-
2.
The 6.2-kb PCR product encompassing the TNXB gene to the 3’-end of the CYP21 gene: In order to understand the status of the CYP21 gene within the RCCX module after gene deletion or conversion, a strategy of using a 6.2-kb PCR product amplified with locus-specific primers from the tenascin (TNXB) gene to the 5’ end of CYP21P or CYP21 has been successfully achieved (Figs. 1C, 2A) (Lee et al. 2003a,2003b). The sense primer located in tenascin B (TNXB) containing a 120-bp sequence deleted from tenascin A (TNXA) and an antisense primer in the 5’ end of the CYP21P and CYP21 genes were used (Table 3) (Fig. 1C). The 6.2-kb PCR product was further identified either by the ACRS primer to detect CYP21 mutations (Fig. 1B) (Lee et al.1996) or by Taq I digestion directly analyzed on an agarose gel to evaluate the 3.2- and 3.7-kb fragments (Fig. 2A).
Conclusions
Questions regarding gross gene deletion of 30 kb encompassing the C4A and CYP21 genes have arisen because there is no information on the deleted region in the RCCX module. The chimeric CYP21P/CYP21 is a consequence of the deletion of the complete XA, RP2, and C4B, and partial CYP21P/CYP21 genes of 26 or 32 kb, depending on whether C4B is a long or short gene. Therefore, presentation of a 3.2-kb fragment produced by Taq I digestion is not only a single CYP21 deletion but there is also a chimera included. A previous strategy (Krone et al. 1998) using the Taq I restriction enzyme was applied to specifically disrupt the CYP21P gene for identification of the CYP21 mutation, which may possibly cause a loss of amplification of the chimera. Results of a recent study (Lee et al. 2003b) indicated that the haplotype of the CYP21 allele with the mutation IVS2–12A/C>G combined with 707–714delGAGACTAC is not a chimeric CYP21P/CYP21 gene but does show a 3.2-kb fragment by Taq I digestion. Therefore, we believe that the diversity of haplotypes of the CYP21 allele with the 3.2-kb fragment may frequently occur in CAH patients with steroid 21-hydroxylase deficiency.
References
Bristow J, Tee MK, Gitelman SE, Mellon SH, Miller WL (1993) Tenascin-X: a novel extracellular matrix protein encoded by the human XB gene overlapping P450c21B. J Cell Biol 122:265–278
Chang SF, Chung Bc (1995) Difference in transcriptional activity of two homologous CYP21A genes. Mol Endocrinol 9:1330–1336
Chu X, Braun-Heimer L, Rittner C, Schneider PM (1992) Identification of the recombination site within the steroid 21-hydroxylase gene (CYP21) of the HLA-B47, DR7 haplotype. Exp Clin Immunogenet 9:80–85
Collier S, Sinnott PJ, Dyer PA, Price DA, Harris R, Strachan T (1989) Pulsed field gel electrophoresis identifies a high degree of variability in the number of tandem 21-hydroxylase and complement C4 gene repeats in 21-hydroxylase deficiency haplotypes. EMBO J 8:1393–1402
Day DJ, Speiser PW, White PC, Barany F (1995) Detection of steroid 21-hydroxylase alleles using gene-specific PCR and a multiplexed ligation detection reaction. Genomics 29:152–162
Day DJ, Speiser PW, Schulze E, Bettendorf M, Fitness J, Barany F, White PC (1996) Identification of non-amplifying CYP21 genes when using PCR-based diagnosis of 21-hydroxylase deficiency in congenital adrenal hyperplasia (CAH) affected pedigrees. Hum Mol Genet 5:2039–2048
Donohoue PA, Jospe N, Migeon CJ, Van Dop C (1989) Two distinct areas of unequal crossing over within the steroid 21-hydroxylase genes produce absence of CYP21B. Genomics 5:397–406
Gitelman SE, Bristow J, Miller WL (1992) Mechanism and consequences of the duplication of the human C4/P450c21/gene X locus. Mol Cell Biol 12:2124–2134
Helmberg A, Tabarelli M, Fuchs MA, Keller E, Dobler G, Schnegg I, Knorr D, Albert E, Kofler R (1992) Identification of molecular defects causing congenital adrenal hyperplasia by cloning and differential hybridization of polymerase chain reaction-amplified 21-hydroxylase (CYP21) genes. DNA Cell Biol 11:359–368
Higashi Y, Yoshioka H, Yamane M, Gotoh O, Fujii-Kuriyama Y (1986) Complete nucleotide sequence of two steroid 21-hydroxylase genes tandemly arranged in human chromosome: a pseudogene and a genuine gene. Proc Natl Acad Sci USA 83:2841–2845
Higashi Y, Tanae A, Inoue H, Hiromasa T, Fujii-Kuriyama Y (1988a) Aberrant splicing and missense mutations cause steroid 21-hydroxylase [P-450(C21)] deficiency in humans: possible gene conversion products. Proc Natl Acad Sci USA 85:7486–7490
Higashi Y, Tanae A, Inoue H, Fujii-Kuriyama Y (1988b) Evidence for frequent gene conversion in the steroid 21-hydroxylase P-450 (C21) gene: implications for steroid 21-hydroxylase deficiency. Am J Hum Genet 42:17–25
Human Gene Mutation Database (2003)http://uwcmml1s.uwcm.ac.uk/uwcm/mg/search/120605.html. Cited Oct. 2003
Jeffreys AJ, Wilson V, Thein SL (1985) Hypervariable ‘minisatellite’ regions in human DNA. Nature 314:67–73
Koppens PF, Hoogenboezem T, Degenhart HJ (2000) CYP21 and CYP21P variability in steroid 21-hydroxylase deficiency patients and in the general population in the Netherlands. Eur J Hum Genet 8:827–836
Krone N, Roscher AA, Schwarz HP, Braun A (1998) Comprehensive analytical strategy for mutation screening in 21-hydroxylase deficiency. Clin Chem 44:2075–2082
L’Allemand D, Tardy V, Gruters A, Schnabel D, Krude H, Morel Y. (2000) How a patient homozygous for a 30-kb deletion of the C4-CYP21 genomic region can have a nonclassic form of 21-hydroxylase deficiency. J Clin Endocrinol Metab 85:4562–4567
Lee HH (2001) CYP21 mutations and congenital adrenal hyperplasia. Clin Genet 59:293–301
Lee HH, Chang SF (2001) Multiple transcripts of the CYP21 gene are generated by the mutation of the splicing donor site in intron 2 from GT to AT in 21-hydroxylase deficiency. J Endocrinol 171:397–402
Lee HH, Chao HT, Ng HT, Choo KB (1996) Direct molecular diagnosis of CYP21 mutations in congenital adrenal hyperplasia. J Med Genet 33:371–375
Lee HH, Chao HT, Lee YJ, Shu SG, Chao MC, Kuo JM, Chung Bc (1998) Identification of four novel mutations in the CYP21 gene in congenital adrenal hyperplasia in the Chinese. Hum Genet 103:304–310
Lee HH, Chang JG, Tsai CH, Tsai FJ, Chao HT, Chung Bc (2000) Analysis of the chimeric CYP21P/CYP21 gene in steroid 21-hydroxylase deficiency. Clin Chem 46:606–611
Lee HH, Niu DM, Lin RW, Chan P, Lin CY (2002) Structural analysis of the chimeric CYP21P/CYP21 gene in steroid 21-hydroxylase deficiency. J Hum Genet 47:517–522
Lee HH, Chang SF, Lee YJ, Raskin S, Lin SJ, Chao MC, Lo FS, Lin CY (2003a) Deletion of the C4-CYP21 repeat module leading to the formation of a chimeric CYP21P/CYP21 gene in a 9.3-kb fragment as a cause of steroid 21-hydroxylase deficiency. Clin Chem 49:319–322
Lee HH, Chang SF, Tsai FJ, Tsai LP, Lin CY (2003b) Mutation of IVS2 −12 A/C->G in combination with 707–714delGAGACTAC in the CYP21 gene is caused by deletion of the C4-CYP21 repeat module with steroid 21-hydroxylase deficiency. J Clin Endocrinol Metab 88:2726–2729
Levo A, Partanen J (1997) Mutation-haplotype analysis of steroid 21-hydroxylase (CYP21) deficiency in Finland. Implications for the population history of defective alleles. Hum Genet 99:488–497
Miller WL (1988) Gene conversions, deletions, and polymorphisms in congenital adrenal hyperplasia. Am J Hum Genet 42:4–7
Morel Y, David M, Forest MG, Betuel H, Hauptman G, Andre J, Bertrand J, Miller WL (1989) Gene conversions and rearrangements cause discordance between inheritance of forms of 21-hydroxylase deficiency and HLA types. J Clin Endocrinol Metab 68:592–599
Ohlsson G, Muller J, Schwartz M (1999) Genetic diagnosis of 21-hydroxylase deficiency: DGGE-based mutation scanning of CYP21. Hum Mutat 13:385–389
Ordonez-Sanchez ML, Ramirez-Jimenez S, Lopez-Gutierrez AU, Riba L, Gamboa-Cardiel S, Cerrillo-Hinojosa M, Altamirano-Bustamante N, Calzada-Leon R, Robles-Valdes C, Mendoza-Morfin F, Tusie-Luna MT (1998) Molecular genetic analysis of patients carrying steroid 21-hydroxylase deficiency in the Mexican population: identification of possible new mutations and high prevalence of the apparent germ-line mutations. Hum Genet 102:170–177
Schulze E, Bettendorf M, Maser-Gluth C, Decker M, Schwabe U (1998) Allele-dropout using PCR-based diagnosis for the splicing mutation in intron-2 of the CYP21B-gene: successful amplification with a Taq/Pwo-polymerase mixture. Endocr Res 24:637–641
Shen L, Wu LC, Sanlioglu S, Chen R, Mendoza AR, Dangel AW, Carroll MC, Zipf WB, Yu CY (1994) Structure and genetics of the partially duplicated gene RP located immediately upstream of the complement C4A and the C4B genes in the HLA class III region. Molecular cloning, exon-intron structure, composition retroposon, and breakpoint of gene duplication. J Biol Chem 269:8466–8476
Sinnott P, Collier S, Costigan C, Dyer PA, Harris R, Strachan T (1990) Genesis by meiotic unequal crossover of a de novo deletion that contributes to steroid 21-hydroxylase deficiency. Proc Natl Acad Sci USA 87:2107–2111
Smith GR, Kunes SM, Schultz DW, Taylor A, Triman KL (1981) Structure of chi hotspots of generalized recombination. Cell 24:429–436
Speiser PW, White PC, Dupont J, Zhu D, Mercado AB, New MI (1994) Prenatal diagnosis of congenital adrenal hyperplasia due to 21-hydroxylase deficiency by allele-specific hybridization and southern blot. Hum Genet 93:424–428
Tajima T, Fujieda K, Nakayama K, Fujii-Kuriyama Y (1993) Molecular analysis of patient and carrier genes with congenital steroid 21-hydroxylase deficiency by using polymerase chain reaction and single strand conformation polymorphism. J Clin Invest 92:2182–2190
Tusie-Luna MT, White PC (1995) Gene conversions and unequal crossovers between CYP21 (steroid 21-hydroxylase gene) and CYP21P involve different mechanisms. Proc Natl Acad Sci USA 92:10796–10800
Urabe K, Kimura A, Harada F, Iwanaga T, Sasazuki T (1990) Gene conversion in steroid 21-hydroxylase genes. Am J Hum Genet 46:1178–1186
White PC, New MI, Dupont B (1984) HLA-linked congenital adrenal hyperplasia results from a defective gene encoding a cytochrome P-450 specific for steroid 21-hydroxylation. Proc Natl Acad Sci USA 81:7505–7509
White PC, New MI, Dupont B (1986) Structure of human steroid 21-hydroxylase genes. Proc Natl Acad Sci USA 83:5111–5115
White PC, Vitek A, Dupont B, New MI (1988) Characterization of frequent deletions causing steroid 21-hydrxylase deficiency. Proc Natl Acad Sci USA 85:4436–4440
White PC, Speiser PW (2000) Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev 21:245–291
Yang Z, Shen L, Dangel AW, Wu LC, Yu CY (1998) Four ubiquitously expressed genes, RD (D6S45)-SK12W-(SKIV2L)-DOM3Z-RP1(D6S60E), are present between complement component genes factor B and C4 in the class III region of the HLA. Genomics 53:338–347
Yang Z, Mendoza AR, Welch TR, Zipf WB, Yu CY (1999) Modular variations of the human major histocompatibility complex class III genes for serine/threonine kinase RP, complement component C4, steroid 21-hydroxylase CYP21, and tenascin TNX (the RCCX module). A mechanism for gene deletion and disease associations. J Biol Chem 274:12147–12156
Yang YP, Corley N, Garcia-Heras J (2001) Reverse dot-blot hybridization as an improved tool for the molecular diagnosis of point mutations in congenital adrenal hyperplasia caused by 21-hydroxylase deficiency. Mol Diagn 6:193–199
Yu CY (1991) The complete exon-intron structure of a human complement component C4A gene. DNA sequences, polymorphism, and linkage to the 21-hydroxylase genes. J Immunol 146:1057–1066
Acknowledgements
The author thanks Drs. H.T. Chao, Y.J. Lee, F.S. Lo, M.C. Chao, D.M. Nu, S.J. Lin, F.J. Tsai, and L.P. Tsai for donating blood samples of Taiwanese CAH patients from 1994 to the present. This work was supported by King Car Research Foundation from the King Car Food Industrial Co., Taiwan, Republic of China.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lee, HH. The chimeric CYP21P/CYP21 gene and 21-hydroxylase deficiency. J Hum Genet 49, 65–72 (2004). https://doi.org/10.1007/s10038-003-0115-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10038-003-0115-2
Keywords
This article is cited by
-
EMQN best practice guidelines for molecular genetic testing and reporting of 21-hydroxylase deficiency
European Journal of Human Genetics (2020)
-
Congenital Adrenal Hyperplasia (CAH) due to 21-Hydroxylase Deficiency: A Comprehensive Focus on 233 Pathogenic Variants of CYP21A2 Gene
Molecular Diagnosis & Therapy (2018)
-
A new CYP21A1P/CYP21A2chimeric gene identified in an Italian woman suffering from classical congenital adrenal hyperplasia form
BMC Medical Genetics (2009)
-
Genotyping of CYP21A2 for Congenital Adrenal Hyperplasia Screening using Allele-Specific Primer Extension followed by Bead Array Hybridization
Molecular Diagnosis & Therapy (2009)